|
03 Feb 2021 |
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
|
|
03 Feb 2021 |
COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate against COVID-19
|
|
03 Feb 2021 |
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
|
|
01 Feb 2021 |
SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors
|
|
29 Jan 2021 |
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
|
|
29 Jan 2021 |
COVID-19 Vaccine AstraZeneca recommended for use in the EU
|
|
29 Jan 2021 |
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
|
|
28 Jan 2021 |
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein
|
|
26 Jan 2021 |
Providence Therapeutics announces first subject has been dosed in COVID-19 vaccine trial
|
|
26 Jan 2021 |
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
|
|
25 Jan 2021 |
BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program
|
|
25 Jan 2021 |
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
|
|
25 Jan 2021 |
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
|
|
24 Jan 2021 |
Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch
|
|
21 Jan 2021 |
First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
|
|
21 Jan 2021 |
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea
|
|
21 Jan 2021 |
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
|
|
21 Jan 2021 |
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
|
|
21 Jan 2021 |
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
|
|
20 Jan 2021 |
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
|
|
13 Jan 2021 |
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
|
|
12 Jan 2021 |
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
|
|
12 Jan 2021 |
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19
|
|
11 Jan 2021 |
Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC, a Single Dose, Intranasal, Live Attenuated Vaccine for COVID-19
|
|
10 Jan 2021 |
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
|
